Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in Ulcerative Pyoderma Gangrenosum
NCT06624670Phase 3Recruiting
- Sponsor
- LEO Pharma
- Start
- Feb 2025
- Primary completion
- Nov 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of spesolimab in pyoderma gangrenosum (PG), sponsored by LEO Pharma. Started Feb 2025; status: recruiting.
02
Drugs
spesolimab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT06624670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06624670.